Image description

Published yearly: 

4 Issues


ISSN: 2320-964X (Online) 

ISSN: 2320-7817  (Print)



Dr. Santosh Pawar 




Int. Journal of Life Sciences, 2018; 6(2): 477-486       |                 Available online, April 26, 2018

Polymorphism of Cytochrome P450 epoxygenase and its association with Endothelial Dysfunction in Patients with Coronary Artery Disease 

Gopal Sowjenya  1Durgaprasad Rajasekhar  1 , Velam Vanajakshamma1, PVLN Srinivasa Rao2 ,

PVGK Sarma 3


1Department   of Cardiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, A.P.

2Department   of   Biochemistry, Sri Venkateswara Institute of Medical Sciences, Tirupati, A.P.

3Department   of   Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati, A.P.

*Corresponding Author: Dr. D. RAJASEKHAR, M.D., D.M., FACC., FESC., FSCAI., Senior Professor and Head, Department of Cardiology, Sri Venkateswara Institute of Medical Sciences, Tirupati - 517507, A.P. Phone: +91-9849221650   |    E-mail:


Received : 05.02.2018     |            Accepted : 29.03.2018     |       Published : 26.04.2018

Background: Cytochrome P450 (CYP) epoxygenase metabolise arachidonic acid (AA) into four epoxyeicosatrienoic acids (EETs) 5,6- EETs, 8,9 EETs, 11,12-EETs and 14,15-EETs.  Since, EETs are unstable eicosanoids they rapidly get converted into dihydroxy eicosa trienoicacids (DHETs) by Soluble epoxy hydrolase (sEH). These eicosanoids promote defence mechanism against inflammatory atherosclerosis process. However, 11,12-EETs are more potent eicosanoids in maintaining anti-atherosclerotic  activity. Endothelial dysfunction is the key step in the pathogenesis of atherosclerosis. Polymorphism in CYP epoxygenase can alter individual’s risk for events in coronary artery disease (CAD) patients. Therefore, we examined the impact of CYP epoxygenase polymorphism indirectly through evaluation of 11,12-DHET levels and its association with endothelial dysfunction.

Methods: It is a prospective case-control study consisting of 84 acute coronary syndrome (ACS) patients and 84 healthy controls of either gender aged above 18 years. Fasting serum lipid profile including total cholesterol (TC), high density lipid (HDL), triglycerides (TG) and homocysteine levels were measured in all subjects. We measured plasma 11,12-dihydroxyeicosatrienoic acid (11,12-DHET) as indicative of 11,12-EETs. Genotyping of CYP putative exons of CYP2C9, CYP2C19 and CYP2J2 epoxygenase were carried out by Polymerase Chain Reaction–Single Strand Conformation Polymorphism (PCR-SSCP) method. Sanger’s chain termination sequencing method was carried out for SSCP positive samples. All the data obtained were analysed by using Ms-Excel, 2007 and SPSS, version 24.Software, IBM, USA.

Results: We observed significantly higher levels of  homocysteine in CAD group (35.1 ± 13.8 µmol/L) indicating higher inflammatory condition in patients compared to control group (8.1 ± 2.9 µmol/L, p < 0.001). We also found higher 11,12-DHET levels  in CAD group  (628.6 ± 324.3 pg/mL) compared to healthy controls (332.1 pg/mL ± 203.2 pg/mL, p = 0.0001). In this connection, we observed positive correlation between homocysteine levels and 11,12- DHETs in CAD group (p = 0.01). Genotyping of CYP exons revealed 11 patients (13%) reporting 12 single nucleotide polymorphisms (SNPs). We found significant difference in the levels of 11,12- DHETs between the patients reporting CYP polymorphism and patients without CYP polymorphism compared with the control (p<0.001). Further, we observed negative correlation between homocysteine levels and 11,12-DHETs in CAD patients reporting CYP polymorphisms indicating decline of DHET mediated anti-atherosclerotic activity

Conclusions: Presence of lower levels of 11,12- DHETs is a reflection of poor reserve defence mechanism in CAD patients that might cause endothelial dysfunction and risk of  cardiac events. Therefore, genotyping of CYP2C9, CYP2C19 and CYP2J2 genes can be recommended to be used as prognostic marker for risk stratification in CAD patients.


Keywords: Polymorphism, Cytochrome P450 epoxygenase, Endothelial function and Acute coronary syndrome patients.


Editor: Dr.Arvind Chavhan


Cite this article as:

Gopal Sowjenya, Durgaprasad Rajasekhar, Velam Vanajakshamma, PVLN Srinivasa Rao, PVGK Sarma(2018) Polymorphism of Cytochrome P450 epoxygenase and its association with Endothelial Dysfunction in Patients with Coronary Artery Disease, Int. J. of. Life Sciences, Volume 6(2): 477-486. 



We gratefully thank Sri Balaji Arogya Varaprasadini (SBAVP) scheme of our institution for partial financial support to carry out this work.


Conflicts of interest: The authors stated that no conflicts of interest.



Copyright: © 2018 | Author(s), This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial - No Derives License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.



Akasaka T, Sueta D, Arima Y, Tabata N, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Ogata Y, Matsui K and Hokimoto S (2016) Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular kangina. Am J Physiol Heart Circ Physiol.311 (6):H1409-H1415.

Arima Y, Hokimoto S, Akasaka T, Mizobe K, Kaikita K, Oniki K Nakagawa K and Ogawa H  (2015) Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. J Cardiol.65: 494–500.

Arun Kumar AS , Kumar SS , Umamaheswaran G , Kesavan R , Balachandar J and Adithan  C (2015) Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population. Pharmacol Rep.67(1):97101.

Aspromonte N, Monitillo F, Puzzovivo A, Valle R, Caldarola P and Iacoviello M. (2014) Modulation of cardiac cytochrome P450 in patients with heart failure. Expert Opin Drug Metab Toxicol.10(3):327-39.

Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, Turner RM, Thomson SG  and Kooner JS (2000) Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet.355(903):523-7.

Crespi CL and Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics.7(3):203-10.

Feletou M, Kohler R and Vanhoutte PM (2010) Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment Targets. Curr Hypertens Rep.12:267–275.

Hadi HA, Carr CS and Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.Vascular Health and Risk Management. 1(3):183-198.

Harrison M, Maressco K and Broeckel U (2008) Genetic determinants of hypertension:  an update. Curr Hypertens Rep.10:488-495.

Haynes WG (2002) Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins. Cardiovasc Drugs Ther.16:391-9.

Hokimoto S, Tabata N, Akasaka T, Arima Y, Kaikita K, Morita K,Kumagae N, Oniki K, Nakagawa K and Ogawa H (2015) Gender differences inimpact of CYP2C19 polymorphism on development of coronary artery disease. J Cardiovasc Pharmacol. 65: 148–152.

Indrayan A (2005) Forecasting vascular disease cases and associated mortality in India. Reports of the National Commission on Macroeconomics and Health, Ministry of Health and Family Welfare, India,

Jatin D P, Kirankumar P C, Chandan C and Hiran I S (2017) Homocysteine level in Coronary artery disease patients of Ahmedabad population. Int J of Med sci and Pub health.6(3): 558-563.

Jorge H. C, John R. Falck, and Raymond C. H (2000) Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monoxygenase. J.Lipid Research.41: 163-181.

Jose R, Chandra sekharan A, Sam S S, Gerard N, Chanolean S, Abraham B K, K S, Peter A and  Rajagopal K (2004) CYP2C9 and CYP2C19  genetic polymorphisms: frequencies in the south Indian population. Fundamental & clinical Pharmacology.19:101-05.

Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids Res.16:1215.

Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K Zeldin DC and Liao JK.(1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 20;285(5431):1276-9.

Oni-Orisan A, Alsaleh N, Lee CR and Seubert JM (2014) Epoxyeicosatrienoic acids and cardioprotection: The road to translation. Journal of Molecular and Cellular Cardiology. 74:199–208.

Packard R and Libby P (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem.54(1):124-38.

Prakash D and Vibhuti S (2005) Coronary Artery Disease in South Asians: Evolving Strategies for Treatment and Prevention. Ind Heart J.57: 617-631.

Petrak O, Widimsky J, Zelinka T. Kvasnicka J, Strauch B, Holaj R, Stulc T, Kvasnicka T,  Bilkova J and Skrha J (2006) Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension.  Physiol. Res. 55: 597-602.

Roberts R and Stewart AF (2012) The genetics of coronary artery disease. Curren opini cardi. 27:221-27.

Shahabi P, Siest G, Meyer UA and Visvikis S (2014) Human cytochrome P450 epoxygenases: variability in expression and role in inflammation related disorders. Pharmacol Ther.144(2):13461.

Shuldiner AR, Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W and Gurbel PA  (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 302(8):849-57.

Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Singh RB1, Mengi SA, Xu YJ, Arneja AS and Dhalla NS (2002) Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol. Spring;  7(1):40-53.

Tantray JA , Reddy KP , Jamil K and Kumar YS (2017)  Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel  therapy. Int J Cardiol.15;229:113-18.

Toth PP (2008) Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract. 62(8):1246-54.

Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE Alyman RB (2010) Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics.20(4):277-81.

Widlansky ME, Gokce N, Keaney JJ and Vita, JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol.42:1149-60.

Xu M, Ju W, Hao H, Wang G and Lu P (2013) Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance. Drug metab Rev. 45:311-352.

Yang T, Peng R, Guo Y, Shen L, Zhao S and Xu D (2013) The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids Health Dis. 12: 151.








    Origin & Evolution

    Print ISSN : 2320-7817 

    Online ISSN:2320-964X


    46, Guruwandan, Jawahar Nagar, 

    VMV Road, Amravati- 444604

    Maharashtra, India.

    Tel  + 91- 9970559438  |   9420775527  

    Email: |